| Name | Title | Contact Details |
|---|
Immunovant is a biopharmaceutical company committed to developing innovative therapies that not only treat the symptoms, but modify the course of autoimmune diseases. Our primary investigational product candidate is RVT-1401, a human recombinant anti-FcRn monoclonal antibody that is being developed with a focus on patient need, and may be applicable to a wide array of autoimmune diseases. We are currently assessing RVT-1401 in a single and multiple ascending dose Phase 1 clinical trial. We plan on initiating a number of patient-based studies in early 2019, focusing on Myasthenia gravis (MG) and other IgG-mediated diseases. We also seek to continue expanding our pipeline, ultimately transforming the lives of patients with autoimmune diseases.
EUSA Pharma Corporation is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
OmniActive was born from Kancor Ingredients, an ingredient supplier rooted in the food and flavoring industry. Kancor has decades of experience extracting pure, quality ingredients from whole foods. With a history in extraction of natural products dating back to 1969, we at OmniActive are well versed in the technologies and processes necessary to provide specialized ingredients to the supplements space, as well as food and beverage companies. Kancor and OmniActive were both founded by the Mariwala family, with a long heritage in the spice industry. Patriarch Kanji Moorarji began trading in spices in 1857, an interest that continues to the present day. This history is reflected in the strength of our supply chain and raw material sourcing.
The Protein Data Bank (PDB) was established as the 1st open access digital data resource in all of biology and medicine. It is today a leading global resource for experimental data central to scientific discovery.
Vaxxas is a privately held biotechnology company focused on enhancing the performance of existing and next-generation vaccines with its proprietary high-density microarray patch (HD-MAP). Vaxxas is targeting initial applications in infectious disease and oncology. In addition to HD-MAP HexaPro clinical studies of a COVID-19 vaccine patch, Vaxxas is performing demonstration work in preparation for clinical evaluation under contract with the United States Biomedical Advanced Research and Development Authority (BARDA) on pandemic vaccination solutions. Vaxxas core technology was initially developed at the University of Queensland. The company was founded with the completion of an initial equity financing led by OneVentures Innovation Fund I with co-investors Brandon Capital Partners, Brandon BioCatalyst, and US-based HealthCare Ventures, followed by a further financing led by OneVentures. OneVentures Innovation Fund I and Brandon BioCatalyst are supported by the Australian Government’s Innovation Investment Fund (IIF) program. The IIF is an Australian Government venture capital initiative that provides investment capital and managerial expertise through licensed venture capital fund managers to investee companies.